Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Thomas

Showing results (71-80 of 102) with videos related to

Pageof 11
Sort By:
BMJ (Clinical Research Ed.)|February 22, 2005
Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trialClive Ballard, Marisa Margallo-Lana, Edmund Juszczak, et al.
Indian Heart Journal|October 15, 2022
Development and validation of a mobile application based on a machine learning model to aid in predicting dosage of vitamin K antagonists among Indian patients post mechanical heart valve replacementM Amruthlal, S Devika, Vignesh Krishnan, et al.
Redox Biology|June 2, 2019
HDL subclass proteomic analysis and functional implication of protein dynamic change during HDL maturationYuling Zhang, Scott M Gordon, Hang Xi, et al.
Journal of Psychopharmacology (Oxford, England)|January 21, 2017
Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for PsychopharmacologyJohn T O'Brien, Clive Holmes, Matthew Jones, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 26, 2022
Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsyLeonidas Chouliaras, Alan Thomas, Maura Malpetti, et al.
Journal of the International Neuropsychological Society : JINS|October 20, 2021
Neuropsychological Impairments and Their Cognitive Architecture in Mild Cognitive Impairment (MCI) with Lewy Bodies and MCI-Alzheimer's DiseaseJoanna Ciafone, Alan Thomas, Rory Durcan, et al.
Journal of Alzheimer'S Disease : JAD|August 12, 2017
PET Tau and Amyloid-β Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid BiomarkersIvan Koychev, Roger N Gunn, Azadeh Firouzian, et al.
Journal of the American Medical Directors Association|December 20, 2014
A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD)Clive Ballard, Alan Thomas, Stephen Gerry, et al.
Epigenetics|August 22, 2024
Genetic architecture of epigenetic cortical clock age in brain tissue from older individuals: alterations in <i>CD46</i> and other lociFrancine Grodstein, Bernardo Lemos, Jingyun Yang, et al.
Nature Genetics|December 13, 2006
Genome variation and evolution of the malaria parasite Plasmodium falciparumDaniel C Jeffares, Arnab Pain, Andrew Berry, et al.
Pageof 11

Showing results (71-80 of 102) with videos related to

Sort By:
Pageof 11
BMJ (Clinical Research Ed.)|February 22, 2005
Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trialClive Ballard, Marisa Margallo-Lana, Edmund Juszczak, et al.
Indian Heart Journal|October 15, 2022
Development and validation of a mobile application based on a machine learning model to aid in predicting dosage of vitamin K antagonists among Indian patients post mechanical heart valve replacementM Amruthlal, S Devika, Vignesh Krishnan, et al.
Redox Biology|June 2, 2019
HDL subclass proteomic analysis and functional implication of protein dynamic change during HDL maturationYuling Zhang, Scott M Gordon, Hang Xi, et al.
Journal of Psychopharmacology (Oxford, England)|January 21, 2017
Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for PsychopharmacologyJohn T O'Brien, Clive Holmes, Matthew Jones, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 26, 2022
Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsyLeonidas Chouliaras, Alan Thomas, Maura Malpetti, et al.
Journal of the International Neuropsychological Society : JINS|October 20, 2021
Neuropsychological Impairments and Their Cognitive Architecture in Mild Cognitive Impairment (MCI) with Lewy Bodies and MCI-Alzheimer's DiseaseJoanna Ciafone, Alan Thomas, Rory Durcan, et al.
Journal of Alzheimer'S Disease : JAD|August 12, 2017
PET Tau and Amyloid-β Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid BiomarkersIvan Koychev, Roger N Gunn, Azadeh Firouzian, et al.
Journal of the American Medical Directors Association|December 20, 2014
A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD)Clive Ballard, Alan Thomas, Stephen Gerry, et al.
Epigenetics|August 22, 2024
Genetic architecture of epigenetic cortical clock age in brain tissue from older individuals: alterations in <i>CD46</i> and other lociFrancine Grodstein, Bernardo Lemos, Jingyun Yang, et al.
Nature Genetics|December 13, 2006
Genome variation and evolution of the malaria parasite Plasmodium falciparumDaniel C Jeffares, Arnab Pain, Andrew Berry, et al.
Pageof 11